US92346J1088 - Common Stock
VERICEL CORP
NASDAQ:VCEL (5/15/2024, 5:12:47 PM)
After market: 49.41 0 (0%)49.41
+0.88 (+1.81%)
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 305 full-time employees. The firm markets two cell therapy products and one specialty biologic product in the United States. MACI (autologous cultured chondrocytes onporcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single ormultiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The firm also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.
VERICEL CORP
64 Sidney St
Cambridge MASSACHUSETTS 02139
P: 17349305555
CEO: Dominick C. Colangelo
Employees: 305
Website: https://vcel.com/
VCEL stock results show that Vericel beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Total Revenue Increased 25% to $51.3 Million Record First Quarter MACI Revenue of $40.2 Million and Burn Care Revenue Growth of 63% Adjusted EBITDA...
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe...
Here you can normally see the latest stock twits on VCEL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: